$ZVRA News

Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Zevra Therapeutics' (NASDAQ:ZVRA) Earnings Aren't As Good As They Appear

Zevra Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference

Zevra Therapeutics, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Guggenheim Maintains Buy on Zevra Therapeutics, Raises Price Target to $25

Is It Too Late To Consider Zevra Therapeutics (ZVRA) After The Recent Share Price Surge?

Zevra Therapeutics Q1 Earnings Call Highlights

Zevra Therapeutics, Inc. Q1 2026 Earnings Call Summary

Zevra Therapeutics, Inc. (ZVRA) Q1 2026 Earnings Call Transcript

Zevra (ZVRA) Q1 2026 Earnings Call Transcript

Zevra Therapeutics (NASDAQ:ZVRA) Shares Surge After Blowout Q1 Earnings Beat

Zevra Reports First Quarter 2026 Financial Results and Corporate Update

CORRECTION: Zevra Therapeutics Q1 Adj. EPS $0.18 Beats $0.08 Estimate, Sales $36.220M Beat $31.960M Estimate

Zevra Therapeutics Announces Details for Q1 2026 Financial Results Call

John B Bode At Zevra Therapeutics Executes Options Exercise, Realizing $326K

Zevra Ties NPC Testing Push To Valuation Gap And New CFO

Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)

Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million

Zevra Shares Jump After Selling SDX Portfolio For $50M

Zevra Therapeutics Agrees To Sell Its Serdexmethylphenidate Portfolio, Including AZSTARYS And KP1077, To Commave Therapeutics For $50M